Track topics on Twitter Track topics that are important to you
The Research Question of the present study is the following: in a group of patients affected by GERD, 1-month treatment with PPI (omeprazole) and Marial® will significantly decrease the use of Gaviscon® as rescue medicine in comparison with patients treated with omeprazole alone.
This is an open-label, comparative, multicenter study with two parallel group of subjects. The clinical investigation will be performed in six clinical sites.
The study population will include subjects affected by GERD with diagnosis of Grade A esophagitis on Los Angeles Classification System grades reflux esophagitis, confirmed by gastroscopy (done within 1 month prior baseline).
Marial® is a class IIa medical device (Directive 93/42/EEC), already marketed in several EU countries. This compound has been produced combining hyaluronic acid, hydrolyzed keratin mucoproteins, glycoproteins such as fibronectin, meso glycans and integrins, and viscous agents. It evidenced to actively regenerate the damaged tissue by repairing and regenerative properties on mucous membranes and by muco-adhesive and film-forming characteristics that allow to prolong the contact time with the mucous membranes and consequently to improve the effectiveness.
Gastroesophageal Reflux Disease
Marial® + PPI (generic omeprazole), PPI alone (generic omeprazole)
Societatea Civilă Medicală Gados
Nekkar Lab Srl
Published on BioPortfolio: 2019-10-23T13:11:48-0400
Proton pump inhibitors (PPI) are used to decrease stomach acid secretion. A generic form of omeprazole, one of the PPIs, is on the market. With cheaper than brand name PPIs, it is unclea...
Patients with gastroesophageal reflux disease (GERD) are either treated for 4 weeks with a standard dose (20mg) of omeprazole, a drug of first choice, or by an individualized dosing (20 or...
The purpose of this study is to compare the efficacy of oral and rectal omeprazole treatment in infants with gastroesophageal reflux due to esophageal atresia or congenital diaphragmatic h...
A Study to Assess the Efficacy, Safety and Tolerability of Tegaserod Alone and in Combination With Omeprazole Given Orally in Patients With Symptoms of Symptomatic Gastroesophageal Reflux Disease (sGERD)
Gastroesophageal Reflux Disease (GERD) is a common disorder caused by the reflux of gastric (stomach) acid into the esophagus. The exposure of the lining of the esophagus to the acid will ...
Wheezy infants were tested for gastro-esophageal reflux disease (GERD) using combined multiple channel intraluminal impedance-pH (MII-pH), esophagogastroduodenoscope (EGD), lipid laden mac...
Omeprazole (OM), a prototype proton pump inhibitor, oxidizes thiol groups and induces DNA damage. The aim of this study was to evaluate the oxidative effects of omeprazole and its interactions with as...
Clinical signs of syringomyelia and hydrocephalus occur secondary to cerebrospinal fluid (CSF) accumulation within the central nervous system. Omeprazole is recommended to treat these conditions despi...
To evaluate the current status of the diagnosis and treatment of gastroesophageal reflux disease (GERD) in patients with nocturnal gastroesophageal reflux (nGER).
Proton pump inhibitors (PPIs) are used by millions of patients for the treatment of stomach acid-reflux diseases. Although PPIs are generally considered safe, about 13% of the users develop hypomagnes...
The aim of this study was to explore the individual effects of the CYP2C19 G681A polymorphism and omeprazole use and their interaction on clopidogrel responsiveness in acute coronary syndrome (ACS). T...
Retrograde bile flow. Reflux of bile can be from the duodenum to the stomach (DUODENOGASTRIC REFLUX); to the esophagus (GASTROESOPHAGEAL REFLUX); or to the PANCREAS.
Back flow of gastric contents to the LARYNGOPHARYNX where it comes in contact with tissues of the upper aerodigestive tract. Laryngopharyngeal reflux is an extraesophageal manifestation of GASTROESOPHAGEAL REFLUX.
The S-isomer of omeprazole.
Chronic ESOPHAGITIS characterized by esophageal mucosal EOSINOPHILIA. It is diagnosed when an increase in EOSINOPHILS are present over the entire esophagus. The reflux symptoms fail to respond to PROTON PUMP INHIBITORS treatment, unlike in GASTROESOPHAGEAL REFLUX DISEASE. The symptoms are associated with IgE-mediated hypersensitivity to food or inhalant allergens.
A highly effective inhibitor of gastric acid secretion used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits the H(+)-K(+)-ATPase (H(+)-K(+)-EXCHANGING ATPASE) in the proton pump of GASTRIC PARIETAL CELLS.
Astroesophageal Reflux Disease (GERD) Barrett's Esophagus Celiac Disease Cholesterol Crohn's Disease Gastroenterology Hepatitis Hepatology Irritable Bowel Syndrome (IBS) Pancreatitis Peptic Ulcer Disease...
The role of medical devices in healthcare is essential. The diversity and innovativeness of this sector contribute significantly to enhance the quality and efficacy of healthcare. Covering a wide range of products, from simple bandages to the...